No connection

Search Results

HQY vs PTCT

HQY
HealthEquity, Inc.
NEUTRAL
Price
$77.96
Market Cap
$6.66B
Sector
Healthcare
AI Confidence
85%
PTCT
PTC Therapeutics, Inc.
NEUTRAL
Price
$72.43
Market Cap
$6.0B
Sector
Healthcare
AI Confidence
80%

Valuation

P/E Ratio
HQY
31.69
PTCT
8.44
Forward P/E
HQY
14.6
PTCT
29.81
P/B Ratio
HQY
3.15
PTCT
-28.74
P/S Ratio
HQY
5.07
PTCT
3.46
EV/EBITDA
HQY
15.08
PTCT
7.55

Profitability

Gross Margin
HQY
69.52%
PTCT
70.98%
Operating Margin
HQY
21.64%
PTCT
-49.57%
Profit Margin
HQY
16.38%
PTCT
39.44%
ROE
HQY
10.19%
PTCT
--
ROA
HQY
5.99%
PTCT
23.26%

Growth

Revenue Growth
HQY
7.3%
PTCT
-22.7%
Earnings Growth
HQY
92.4%
PTCT
--

Financial Health

Debt/Equity
HQY
0.48
PTCT
--
Current Ratio
HQY
3.27
PTCT
2.35
Quick Ratio
HQY
2.82
PTCT
2.2

Dividends

Dividend Yield
HQY
--
PTCT
--
Payout Ratio
HQY
0.0%
PTCT
0.0%

AI Verdict

HQY NEUTRAL

HQY presents a stark divergence between strong fundamental earnings performance and bearish market sentiment. The company maintains a stable financial health profile with a Piotroski F-Score of 4/9 and excellent liquidity (Current Ratio 3.27). While the current price of $77.96 trades at a premium to its intrinsic value ($72.57) and Graham Number ($37.04), the Forward P/E of 14.60 suggests significant expected earnings expansion. However, the bullish fundamental outlook is heavily countered by a 0/100 technical trend and consistent insider selling.

Strengths
Explosive YoY earnings growth of 92.40%
Strong liquidity position with a current ratio of 3.27
Impressive gross margins of 69.52%
Risks
Strongly bearish technical trend (0/100)
Net insider selling activity across multiple executives
Current price exceeds growth-based intrinsic value ($72.57)
PTCT NEUTRAL

PTCT presents a paradoxical profile: it boasts a perfect Piotroski F-Score of 9/9, indicating strong short-term financial improvement, yet suffers from negative revenue growth (-22.70%) and heavy insider selling. While the current P/E of 8.44 appears attractive, the jump to a Forward P/E of 29.81 suggests a significant expected decline in earnings. The stock is currently trading at a premium to its growth-based intrinsic value of $60.06, though analyst targets remain optimistic at $87.87. Overall, the strong balance sheet liquidity (Current Ratio 2.35) offsets the operational volatility, but the lack of growth and insider confidence warrants a neutral stance.

Strengths
Perfect Piotroski F-Score (9/9) indicating strong fundamental health trends
High Gross Margin (70.98%) reflecting strong pricing power or low COGS
Strong liquidity position with a Current Ratio of 2.35
Risks
Significant negative revenue growth (-22.70% YoY and Q/Q)
Heavy insider selling (16 transactions, 0 buys) including CEO and COO
Extreme earnings volatility with massive surprise swings (e.g., -1097.5% recent surprise)

Compare Another Pair

HQY vs PTCT: Head-to-Head Comparison

This page compares HealthEquity, Inc. (HQY) and PTC Therapeutics, Inc. (PTCT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile